Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib+Daratumumab+Dexamethasone in RRMM
NCT03439293Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Started Mar 2018; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03439293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439293.